Imunostimulanti, imunostimulatori, su supstance (lekovi i hranljive materije) koje stimulišu imunski sistem podsticanjem (stimulacijom) ili povećanjem aktivnosti bilo koje komponente imunskog sistema. Jedan značajan primer je GM-CSF (stimulišući faktor kolonija granulocit makrofaga).[1]
Klasifikacija [уреди]
Postoje dve glavne kategorije imunostimulanata:
Deoksiholna kiselina [уреди]
Neke publikacije upućuju na imunostimulantni efekat deoksiholne kiseline (DCA).[8][9][10] DCA dejstvuje na nespecifični imunski sistem, aktivirajući njegov glavni ćelijski tip, makrofage. Prema ovim publikacijama, dovoljna količina deoksiholne kiseline u ljudskom telu bi bila poput snažne imune reakcije nespecifičnog imunskog sistema.
Vidi još [уреди]
Endogeni imunostimulanti [уреди]
Sintetički imunostimulanti [уреди]
Biljni imunostimulanti [уреди]
Literatura [уреди]
- ^ Thomas J. Kindt, Richard A. Goldsby, Barbara Anne Osborne, Janis Kuby (2006). Kuby Immunology (6 ed.). New York: W H Freeman and company. ISBN 1429202114.
- ^ Mattner F, Fleitmann JF, Lingnau K, Schmidt W, Egyed A, Fritz J, Zauner W, Wittmann B, Gorny I, Berger M, Kirlappos H, Otava A, Birnstiel ML, Buschle M (2002). „Vaccination with Poly-L-Arginine As Immunostimulant for Peptide Vaccines: Induction of Potent and Long-Lasting T-Cell Responses against Cancer Antigens“. Cancer Research 62: 1477-1480.
- ^ Cullen CM, Jameson SC, DeLay M, Cottrell C, Becken ET, Choi E, Hirsch R (1999). „A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo“. Cell Immunol 192 (1): 54-62. PMID 10066347.
- ^ Wira, CR; Crane-Godreau M, Grant K (2004). „Endocrine regulation of the mucosal immune system in the female reproductive tract“. In In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J (eds.). Mucosal Immunology. San Francisco: Elsevier. ISBN 0124915434.
- ^ Lang, TJ (2004). „Estrogen as an immunomodulator“. Clin Immunol 113: 224–230. DOI:10.1016/j.clim.2004.05.011. PMID 15507385.
Moriyama, A; Shimoya K, Ogata I et al. (1999). „Secretory leukocyte protease inhibitor (SLPI) concentrations in cervical mucus of women with normal menstrual cycle“. Molecular Human Reproduction 5: 656–661. DOI:10.1093/molehr/5.7.656. PMID 10381821.
Cutolo, M; Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH (2004). „Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity“. Lupus 13: 635–638. DOI:10.1191/0961203304lu1094oa. PMID 15485092.
King, AE; Critchley HOD, Kelly RW (2000). „Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial role“. Molecular Human Reproduction 6: 191–196. DOI:10.1093/molehr/6.2.191. PMID 10655462.
- ^ Dorshkind, K; Horseman ND (2000). „The Roles of Prolactin, Growth Hormone, Insulin-Like Growth Factor-I, and Thyroid Hormones in Lymphocyte Development and Function: Insights from Genetic Models of Hormones and Hormone Receptor Deficiency“. Endocrine Reviews 21: 292–312. DOI:10.1210/er.21.3.292. PMID 10857555.
- ^ Nagpal, Sunil; Songqing Naand and Radhakrishnan Rathnachalam (2005). „Noncalcemic Actions of Vitamin D Receptor Ligands“. Endocrine Reviews 26 (5): 662–687. DOI:10.1210/er.2004-0002. PMID 15798098. .
- ^ Vlček B., Reif A., Seidlova B.: Evidence of the participation of deoxycholate in cancer immunity, Z.Naturforsch. 26 b, 419-424 (1971)
- ^ Vlček B.: Potentiation of the immune response with DCA (czech), Prakt.Lekar 52, 326-330 (1972)
- ^ Chyle M., Chyle P.: Regulation of the immune response with DCA (czech, engl. summary), Sbornik lek. 84, 212-218 (1982)
- ^ Djeraba A, Quere P (2000). „In vivo macrophage activation in chickens with Acemannan, a complex carbohydrate extracted from Aloe vera“. Int J Immunopharmacol 22 (5): 365-72.
- ^ Soltanian S, Stuyven E, Cox E, Sorgeloos P, Bossier P (2009). „Beta-glucans as immunostimulant in vertebrates and invertebrates“. Critical Reviews in Microbiology 35 (2): 109-138. DOI:10.1080/10408410902753746.
Spoljašnje veze [уреди]
|
Imunomodulatori: Imunosupresivni lekovi / Imunosupresanti (L04) |
|
Intracelularni
(inicijacija) |
|
|
Intracelularni
(recepcija) |
|
|
| Ekstracelularni |
|
|
|
|
|
Serum cilj
(non-celularni)
|
|
|
|
Celularni ciljevi
|
CD3 ( Muromonab-CD3, Oteliksizumab, Teplizumab, Visilizumab) • CD4 ( Klenoliksimab, Keliksimab, Zanolimumab) • CD11a ( Efalizumab) • CD18 ( Erlizumab) • CD20 ( Afutuzumab, Ocrelizumab, Pascolizumab) • CD23 ( Lumiliksimab) • CD40 ( Teneliksimab, Toralizumab) • CD62L/L-selektin ( Aselizumab) • CD80 ( Galiksimab) • CD147/Basigin ( Gavilimomab) • CD154 ( Ruplizumab)
BLyS (Belimumab) • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliksimab, Daklizumab, Inolimomab)
T-limfocit ( Zolimomab aritoks)
|
|
|
Nesortirani
|
Atorolimumab, Cedelizumab, Dorliksizumab, Fontolizumab, Gantenerumab, Gomiliksimab, Maslimomab, Morolimumab, Pekselizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritoks, Vapaliksimab, Vepalimomab
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja). |
